Get the Stockscreener App
15.05
3.51%
0.51
After Hours:
15.00
-0.05
-0.33%
Pacira Biosciences Inc stock is traded at $15.05, with a volume of 652.95K.
It is up +3.51% in the last 24 hours and down -3.28% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
See More
Previous Close:
$14.54
Open:
$14.5
24h Volume:
652.95K
Relative Volume:
0.47
Market Cap:
$684.75M
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
167.22
EPS:
0.09
Net Cash Flow:
$173.19M
1W Performance:
+5.39%
1M Performance:
-3.28%
6M Performance:
-48.49%
1Y Performance:
-50.95%
1-Day Range:
$14.35
$15.07
1-Week Range:
$13.79
$15.07
52-Week Range:
$11.16
$35.95
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
813-553-6680
Address
5401 WEST KENNEDY BOULEVARD, TAMPA, NJ
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Pacira BioSciences' SWOT analysis: stock faces patent challenges amid growth initiatives - Investing.com UK
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Pacira Pharmaceuticals Announces CFO Transition and Interim Replacement - TipRanks
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Bought by Marshall Wace LLP - MarketBeat
Pacira to present new gene therapy data for knee osteoarthritis By Investing.com - Investing.com Australia
Doma Perpetual Capital Management LLC Has $28.63 Million Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira Announces the Presentation of 104-Week Safety and - GlobeNewswire
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up After Analyst Upgrade - MarketBeat
DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders - Yahoo Finance
Pacira BioSciences (NASDAQ:PCRX) Price Target Increased to $18.00 by Analysts at Jefferies Financial Group - MarketBeat
Expert Ratings For Pacira BioSciences - Benzinga
Pacer Advisors Inc. Purchases 590,082 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
How To Trade (PCRX) - Stock Traders Daily
A stock that deserves closer examination: Pacira BioSciences Inc (PCRX) - US Post News
Renaissance Technologies LLC Buys 184,000 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Riding the Waves: A Guide to Investing in PCRX Stock - The InvestChronicle
Pacira BioSciences (NASDAQ:PCRX) Trading 6.7% Higher - MarketBeat
Analysts review Pacira BioSciences Inc’s rating - Knox Daily
Insider’s View: Deciphering Pacira BioSciences Inc (PCRX)’s Financial Health Through Ratios - The Dwinnex
Pacira BioSciences, Inc. (NASDAQ:PCRX) Short Interest Up 17.5% in August - MarketBeat
Pacira BioSciences (NASDAQ:PCRX) Sees Strong Trading Volume - MarketBeat
Views of Wall Street’s Leading Experts on Pacira BioSciences Inc - SETE News
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
WINTON GROUP Ltd Makes New $2.73 Million Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira BioSciences COO sells shares worth over $6,000 By Investing.com - Investing.com Australia
Pacira BioSciences COO sells shares worth over $6,000 By Investing.com - Investing.com Canada
Pacira BioSciences COO sells shares worth over $6,000 By Investing.com - Investing.com UK
Pacira BioSciences COO sells shares worth over $6,000 - Investing.com India
Pacira BioSciences COO sells shares worth over $6,000 - Investing.com
Thornburg Investment Management Inc. Makes New $5.40 Million Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira BioSciences Inc [NASDAQ: PCRX] Sees Decrease in Stock Value - Knox Daily
Rice Hall James & Associates LLC Has $28.57 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
A year in review: Pacira BioSciences Inc (PCRX)’s performance in the last year - US Post News
PCRXPacira BioSciences, Inc. Latest Stock News & Market Updates - StockTitan
Pacira BioSciences (NASDAQ:PCRX) Trading Down 4.4% - MarketBeat
Pacira director retains board seat despite shareholder dissent - Investing.com
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - StockTitan
Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34% - Simply Wall St
Lisanti Capital Growth LLC Invests $3.97 Million in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
72,992 Shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) Acquired by Rothschild Investment LLC - MarketBeat
Short Interest in Pacira BioSciences, Inc. (NASDAQ:PCRX) Declines By 18.4% - MarketBeat
Banco Santander S.A. Takes $3.96 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira To Appeal Generic's Win In Pain Drug Patent Fight - Law360
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by Legato Capital Management LLC - MarketBeat
Rival Can't Avoid Drugmaker's False Ad Claim Over Pain Med - Law360
(PCRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Baillie Gifford & Co. Lowers Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Delaware Lets Ventis Move Pacira's False Ad Suit To Calif. - Law360
Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock Position Lowered by Assenagon Asset Management S.A. - MarketBeat
Hennion & Walsh Asset Management Inc. Makes New $1.01 Million Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):